Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
426
-
Total 13F shares, excl. options
-
89.7M
-
Shares change
-
-369K
-
Total reported value, excl. options
-
$8.74B
-
Value change
-
-$27.5M
-
Put/Call ratio
-
0.3
-
Number of buys
-
209
-
Number of sells
-
-197
-
Price
-
$97.48
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q2 2022
487 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q2 2022.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 426 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.7M shares
of 99.6M outstanding shares and own 90.04% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.9M shares), VANGUARD GROUP INC (8.9M shares), JANUS HENDERSON GROUP PLC (5.21M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.96M shares), STATE STREET CORP (3.77M shares), JPMORGAN CHASE & CO (3M shares), Bellevue Group AG (2.84M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.01M shares), Bank of New York Mellon Corp (1.7M shares), and EATON VANCE MANAGEMENT (1.47M shares).
This table shows the top 426 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.